Start Curse client not updating add ons

Curse client not updating add ons

I’ve been paying close attention to the blogs being published by the Center for Why should the health system pay the same price, on a per-dose basis, for a drug that is only 40 percent effective in treating psoriasis versus 75 percent effective in relieving the symptoms of psoriatic arthritis?

In brief, should a drug add major benefits, considerable benefits, or some moderate improvement against the standards-of-care on the market, the manufacturer and the insurance provider organization in Germany enter into negotiations over pricing.

But I have concerns about Mehr’s discussion on applying the concept to biosimilars — at least this early in the biosimilar game when education of physicians is key.

He writes: What if, to help clinicians gain comfort with the biosimilar and increase rapid uptake, the indication for which the medication was clinically tested was priced at a lower level than for other indications?

It would also suggest the biosimilar is more effective in those conditions, solely because it went through clinical trials.